Arrevus’s CF Oral Antibiotic ARV-1801 Receives FDA Orphan Drug Status
The U.S. FDA has granted orphan drug status to ARV-1801 (sodium fusidate tablets), an oral antibiotic developed by Arrevus for cystic fibrosis patients. Read more here.
What do you think of this news?
Sorry, there were no replies found.
Log in to reply.